Rocket Pharmaceuticals (RCKT) Cash from Investing Activities (2015 - 2026)

Rocket Pharmaceuticals has disclosed Cash from Investing Activities across 12 years of filings, most recently posting $17.4 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $17.4 million, up 130.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $179.2 million (up 363.93% YoY), and the FY2025 annual result was $103.8 million, down 21.21% from the prior year.
• Cash from Investing Activities came in at $17.4 million for Q1 2026 at Rocket Pharmaceuticals, down from $36.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $93.6 million in Q3 2025 to a low of -$140.8 million in Q4 2023.
• The 5-year median for Cash from Investing Activities is $31.2 million (2023), against an average of $5.0 million.
• Peak annual rise in Cash from Investing Activities reached 229.01% in 2022, while the deepest fall reached 743.89% in 2022.
• Rocket Pharmaceuticals' Cash from Investing Activities stood at -$108.6 million in 2022, then slipped by 29.67% to -$140.8 million in 2023, then soared by 73.1% to -$37.9 million in 2024, then soared by 196.18% to $36.4 million in 2025, then tumbled by 52.1% to $17.4 million in 2026.
• The last three Cash from Investing Activities figures came in at $17.4 million (Q1 2026), $36.4 million (Q4 2025), and $93.6 million (Q3 2025), per Business Quant data.